Receptor modification as a therapeutic approach against viral diseases
- PMID: 22553391
- PMCID: PMC3338978
- DOI: 10.6026/97320630008331
Receptor modification as a therapeutic approach against viral diseases
Abstract
Poliovirus causes flaccid paralysis through the destruction of motor neurons in the CNS. Susceptibility to its infection is mainly due to the interaction in between the surface capsid proteins and its receptors on the host cell surface, important for binding, penetration and other necessary events during early infection. Receptor modification is a new approach to treat viral diseases by the modification of target proteins structure. Binding domains are modified in an effective way to make it difficult for the virus to recognize it. In this study, tolerant and intolerant induced mutations in the poliovirus receptor, VP1 and VP2 were identified and substituted in the seed sequence to get the modified versions. Substitutions causing changes in initial folding were short listed and further analyzed for high level folding, physiochemical properties and interactions. Highest RMSD values were observed in between the seed and the mutant K90F (3.265 Å) and Q130W (3.270Å) respectively. The proposed substitutions were found to have low functional impact and thus can be further tested and validated by the experimental researchers. Interactions analyses proved most of the substitutions having decreased affinity for both the VP1 and VP2 and thus are of significant importance against poliovirus. This study will play an important role for bridging computational biology to other fields of applied biology and also will provide an insight to develop resistance against viral diseases. It is also expected that same approach can also be applicable against other viruses like HCV, HIV and other in near future.
Keywords: Poliovirus; docking; modification; receptor; structure prediction; substitution.
Figures
Similar articles
-
Molecular characterization of mouse-virulent poliovirus type 1 Mahoney mutants: involvement of residues of polypeptides VP1 and VP2 located on the inner surface of the capsid protein shell.J Virol. 1993 Jul;67(7):3808-17. doi: 10.1128/JVI.67.7.3808-3817.1993. J Virol. 1993. PMID: 8389907 Free PMC article.
-
H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.Antiviral Res. 2014 Oct;110:1-9. doi: 10.1016/j.antiviral.2014.07.003. Epub 2014 Jul 17. Antiviral Res. 2014. PMID: 25043639
-
Mutations in the poliovirus P1 capsid precursor at arginine residues VP4-ARG34, VP3-ARG223, and VP1-ARG129 affect virus assembly and encapsidation of genomic RNA.Virology. 1994 Feb 15;199(1):20-34. doi: 10.1006/viro.1994.1094. Virology. 1994. PMID: 8116243
-
Early events in poliovirus infection: virus-receptor interactions.Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11378-81. doi: 10.1073/pnas.93.21.11378. Proc Natl Acad Sci U S A. 1996. PMID: 8876143 Free PMC article. Review.
-
Molecular mechanisms of poliovirus persistence: key role of capsid determinants during the establishment phase.Cell Mol Life Sci. 1998 Dec;54(12):1385-402. doi: 10.1007/s000180050261. Cell Mol Life Sci. 1998. PMID: 9893712 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
Research Materials